Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2005
11/16/2005CN1697651A 1-phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence
11/16/2005CN1696300A Arachidonic acid and methods for the production and use thereof
11/16/2005CN1227265C Antibodies to CCR5
11/16/2005CN1227261C Monocyclic compounds with four bifunctional residues having NK-2 antagonist action, its preparation, medicine compositions and uses
11/16/2005CN1227248C Imidazolidine derivatives, their preparation, and their use as antinflamatory agent
11/16/2005CN1227241C Arylpiperazines having activity at the serotnin 1A receptor
11/16/2005CN1227237C Piperazinylpyrazines compounds as antagonists of serotonin-5-HT2 receptor
11/16/2005CN1227233C 5-chloro-3-(4-methane sulfonylphenyl)-6-methyl-[2,3'] bipyridine and process for synthesis
11/16/2005CN1227230C Prodrugs to NMDA receptor lagans
11/16/2005CN1227033C Method of treating cancer with anti-neurotrophin agents
11/16/2005CN1227030C Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
11/16/2005CN1227011C Method of treating adenosine depletion
11/15/2005US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
11/15/2005US6965018 Antibodies directed to B7-related polypeptide, BSL-2
11/15/2005US6964984 Preventing desensitization of receptors
11/15/2005US6964981 Therapeutic treatment or prevention of physiological disorders associated with an excess of tachykinins, with neurokinin 1 (NK-1) receptor antagonists; a 2-phenyl-2-(3-phenyl-tetrahydrofuran-2-yloxy)- ethanol
11/15/2005US6964978 Dissolving with crystal growth inihibitos; drying
11/15/2005US6964975 Isoxazole and thiazole compounds and use thereof as medicine
11/15/2005US6964972 8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964965 Corticotropin releasing factor antagonists
11/15/2005US6964962 A norepinephrine reuptake inhibitor or its salt and a neuroleptic agent
11/15/2005US6964960 Indoloquinazolinones
11/15/2005US6964958 Benzodiazepine-3-carboxamide derviatives
11/15/2005US6964957 For use in therapy of neurodegenerative diseases and certain cancers
11/15/2005US6964956 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization
11/15/2005US6964955 Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
11/15/2005US6964953 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
11/15/2005CA2387517C Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
11/15/2005CA2343148C Quick release pharmaceutical compositions of drug substances
11/15/2005CA2130944C Ortho-substituted benzoylguanidines, process for their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them
11/10/2005WO2005106473A1 Method of screening therapeutic agent for neurodegenerative disease
11/10/2005WO2005105998A1 HUMAN ANTIAMYLOID β PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF
11/10/2005WO2005105995A2 RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/10/2005WO2005105743A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof
11/10/2005WO2005105722A1 Crystal comprising (2r)-2-propyloctoic acid and amine
11/10/2005WO2005105120A2 Pharmaceutical combination, active on central nervous system (cns) and set of pharmaceuticals; method of treatment of cns-disorders; means facilitating penetration of the hematoencephalic barrier; pharmaceutical means for endonasal administration
11/10/2005WO2005105089A1 Remedy for psychoneurotic diseases
11/10/2005WO2005105082A1 Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
11/10/2005WO2005105063A1 Pharmaceutical compositions containing serms for the treatment of alzheimer's disease
11/10/2005WO2005002672A3 Sirt1 modulators for manipulating cells/organism lifespan/stress response
11/10/2005WO2004069142A8 Anti-candida agents for the treatment of prion diseases
11/10/2005US20050250939 Process for the production of multiple cross-linked hyaluronic acid derivatives
11/10/2005US20050250881 Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
11/10/2005US20050250851 Methods for treating neuropsychiatric disorders
11/10/2005US20050250848 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
11/10/2005US20050250847 Use of a dicarbamate enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein a monocarbamate enantiomer predominates in preventing or treating neuropathic pain
11/10/2005US20050250846 Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
11/10/2005US20050250843 synergistic antihypoxic mixture: acetylcholine esterase inhibitor (Donepezil and Tacrine) and neuroprotectant 1-[3-(2-(1-benzothiophen-5-yl)ethoxy)propyl]-3-azetidinol maleate; dysfunction of cerebral acetylcholine neurons in sequelae of cerebrovascular and senile dementia, Alzheimer's disease
11/10/2005US20050250834 11-(Aminoalkyl)isoindolo[2,1-a]indol-6-ones: 11-(2-Dimethylaminoethyl)-2-fluoroisoindolo[2,1-a]indol-6-one; psychological disorders, drug abuse, sleep disorders, Alzheimer's, Parkinson's and Huntington's disease, Irritable bowel syndrome, chemotherapy induced emesis, spinal trauma and/or head injury
11/10/2005US20050250813 Injectable depot formulation comprising crystals of iloperidone
11/10/2005US20050250812 Methods for treating lewy body dementia
11/10/2005US20050250807 Neurotrophin antagonist compositions
11/10/2005US20050250802 Novel substituted amines of spirofuropyridines useful in therapy
11/10/2005US20050250792 Substituted piperidine compounds useful as modulators of chemokine receptor activity
11/10/2005US20050250771 Substituted indoles and their use as integrin antagonists
11/10/2005US20050250760 1-[(Indol-3-yl)carbonyl]piperazine derivatives
11/10/2005US20050250715 Remedy
11/10/2005US20050250203 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
11/10/2005US20050250196 Recombinant microorganisms expressing an oligosaccharide receptor mimic
11/10/2005US20050250167 Purified pkb ser 473 kinase and uses thereof
11/10/2005US20050249831 Herbal extract comprising a mixture of saponins obtained from sapindus trifoliatus for anticonvulsant activity
11/10/2005US20050249727 Prevention and treatment of amyloidogenic disease
11/10/2005US20050249725 Improving cognitive function of individuals with beta amyloid disfunction utilizing beta amyloid specific immunoglobulin; immunotherapeutics
11/10/2005US20050249714 Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders
11/10/2005US20050249704 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
11/10/2005DE102004019492A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
11/10/2005DE102004018363A1 Medicament, useful for the treatment of e.g. cancer and AIDS, comprises components and/or extracts of e.g. Prunus armenica, Cocos nucifera, Humulus lupulus, germinated barley/rye/wheat and Myceten as active agents
11/10/2005CA2566196A1 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
11/10/2005CA2564994A1 Substituted morpholine compounds for the treatment of central nervous system disorders
11/10/2005CA2564432A1 Human anti-amyloid .beta. peptide antibody and fragment of said antibody
11/10/2005CA2564390A1 Il-6 for therapy or prevention of chemotherapy-induced neuropathy
11/10/2005CA2564368A1 Chemical compounds
11/10/2005CA2564177A1 Caspase-2 inhibitors and their biological applications
11/10/2005CA2563849A1 Il6r/il6 chimera for therapy of chemotherapy-induced peripheral neuropathy
11/10/2005CA2560165A1 Solid pharmaceutical form comprising an ltb4 antagonist
11/09/2005EP1593683A2 Dihydro-2,3-Benzodiazepine derivatives
11/09/2005EP1593679A1 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
11/09/2005EP1593676A1 8-Chloro-11-(4-(2'-hydroxyethyl)piperazin-1-yl)-dibenzo[b,f][1,4]oxazepine of atypical anti-psychotic activity and having a low affinity for the dopamine D2 receptor
11/09/2005EP1593664A1 Nitric esters derivatives of ferulic acid and sulindac with pharmaceutical activity
11/09/2005EP1593387A1 Compositions for the treatment of impaired interpersonal and behavioral disorders
11/09/2005EP1593379A2 Uses of PPAR-gamma agonists in neutrophil-induced diseases
11/09/2005EP1592772A2 5ht7 antagonists and inverse agonists
11/09/2005EP1592691A1 Pyrazolo[1,5-a][1,3,5]triazine derivatives as cannabinoid receptor ligands
11/09/2005EP1592690A1 Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
11/09/2005EP1592687A1 Benzofurane derivatives and the use of the same as antidepressants and anxiolytics
11/09/2005EP1592683A2 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
11/09/2005EP1592673A2 Novel substituted 2,3-benzodiazepine derivatives
11/09/2005EP1592666A1 2,3 -bipyridines derivatives as selective cox-2 inhibitors
11/09/2005EP1592661A2 Cyclopropyl beta-amino acid derivatives
11/09/2005EP1592464A2 Method of treating cognitive decline due to sleep deprivation and stress
11/09/2005EP1592446A1 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries
11/09/2005EP1592431A1 Method of modulating il-6
11/09/2005EP1592429A1 Method for inhibition of necrosis induced by neurotrophin
11/09/2005EP1592428A1 NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N- 6-(1,1-DIOXO-1&lgr; sp 6 /sp -THIOMORPHOLIN-4-YL)-4(4-F LUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL -N-METHYL-ISOBUTYRAMIDE
11/09/2005EP1592425A2 New arylpiperazinyl compounds
11/09/2005EP1592424A1 Cabergoline for the prophylactic treatment of migraine
11/09/2005EP1592419A1 Use of phosphodiesterase-4 inhibitors as enhancers of cognition
11/09/2005EP1592387A2 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
11/09/2005EP1592386A2 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
1 ... 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 ... 1833